Drug Profile
ALM 201
Alternative Names: ALM-201; FKBPL; FKBPL-derived anticancer peptides; Peptide anti-angiogenic compounds - Queens University Belfast/Almac DiscoveryLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Almac Discovery; Queens University Belfast
- Developer Almac Discovery
- Class Antineoplastics; Peptide fragments
- Mechanism of Action Angiogenesis inhibitors; CD44 antigen modulators; Cell movement inhibitors; Immunophilin modulators; Microtubule protein modulators; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- No development reported Eye disorders; Ovarian cancer; Solid tumours
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for clinical-Phase-Unknown development in Eye-disorders in United Kingdom (Ophthalmic)
- 28 Aug 2021 No recent reports of development identified for phase-I development in Ovarian-cancer in United Kingdom (SC, Injection)
- 28 Aug 2021 No recent reports of development identified for phase-I development in Solid-tumours in United Kingdom (SC, Injection)